Physician profile
Akshey Gupta
NPI 1245249887
$5,550.52
in general payments reported to CMS, 2019-2025
28 companies · $936 in 2025
The $936 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $612 · 2020: $265 · 2021: $719 · 2022: $1,111 · 2023: $1,002 · 2024: $905 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,807 · Education: $35.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,807.30 |
| Education | $35.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $1,039.94 | 2019-2025 | Auryxia, Vafseo |
| Fresenius USA Marketing, INC. | $628.37 | 2019-2025 | Velphoro, Velphoro |
| Amgen INC. | $522.00 | 2019-2025 | Tavneos |
| Mallinckrodt Hospital Products INC. | $518.71 | 2020-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals Lp | $439.29 | 2019-2024 | Farxiga, Lokelma |
| Ani Pharmaceuticals, INC. | $381.63 | 2022-2025 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $328.64 | 2020-2025 | Veltassa, Korsuva |
| Calliditas Therapeutics US INC. | $325.50 | 2022-2025 | Tarpeyo |
| Daiichi Sankyo INC. | $220.76 | 2019-2023 | Injectafer |
| Nxstage Medical, INC. | $168.46 | 2023 | Nxstage System One, Liberty Select Cycler |
| Novo Nordisk INC | $116.15 | 2024-2025 | Wegovy, Ozempic |
| Alexion Pharmaceuticals, INC. | $110.51 | 2022-2023 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $94.51 | 2019-2025 | |
| Travere Therapeutics, INC. | $81.16 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $79.10 | 2019-2025 | Jynarque |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $67.13 | 2024-2025 | Jardiance |
| Mallinckrodt Enterprises LLC | $60.31 | 2019 | |
| Glaxosmithkline, LLC. | $57.94 | 2020-2023 | Jesduvroq |
| Aurinia Pharma U.S., INC. | $57.18 | 2021-2022 | |
| Ardelyx, INC. | $54.14 | 2024-2025 | Ibsrela |
| Ultragenyx Pharmaceutical INC. | $46.04 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $40.45 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $25.90 | 2019-2025 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.52 | 2025 | Jardiance |
| Cormedix INC. | $20.16 | 2024 | Defencath |
| Scpharmaceuticals INC. | $16.91 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.75 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akshey Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.